Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates

By Zacks9 days ago

Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of 6.82%. A quarter ago, it was expected that this specialty pharmaceutical company would post a loss of $0.46 per share when it actually produced a loss of $0.60, delivering a surprise of -30.43%.


Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Aquestive Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $11.12 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 21.55%. This compares to year-ago revenues of $8.77 million. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Continue read on